Wesbanco Bank Inc. lifted its holdings in Zoetis Inc (NYSE:ZTS) by 3,562.8% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 128,015 shares of the company’s stock after buying an additional 124,520 shares during the period. Wesbanco Bank Inc.’s holdings in Zoetis were worth $10,691,000 at the end of the most recent reporting period.
Several other institutional investors have also bought and sold shares of the company. CIBC World Markets Inc. increased its holdings in shares of Zoetis by 290.8% in the 1st quarter. CIBC World Markets Inc. now owns 107,751 shares of the company’s stock worth $8,998,000 after buying an additional 80,181 shares during the last quarter. Moors & Cabot Inc. increased its holdings in shares of Zoetis by 9.9% in the 1st quarter. Moors & Cabot Inc. now owns 17,423 shares of the company’s stock worth $1,455,000 after buying an additional 1,576 shares during the last quarter. Xact Kapitalforvaltning AB increased its holdings in shares of Zoetis by 6.1% in the 1st quarter. Xact Kapitalforvaltning AB now owns 74,379 shares of the company’s stock worth $6,211,000 after buying an additional 4,265 shares during the last quarter. Royal Bank of Canada increased its holdings in shares of Zoetis by 21.0% in the 1st quarter. Royal Bank of Canada now owns 3,192,280 shares of the company’s stock worth $266,588,000 after buying an additional 553,802 shares during the last quarter. Finally, Gables Capital Management Inc. bought a new stake in shares of Zoetis in the 1st quarter worth about $109,000. Hedge funds and other institutional investors own 90.09% of the company’s stock.
Shares of Zoetis opened at $88.93 on Tuesday, Marketbeat.com reports. The stock has a market cap of $43.16 billion, a P/E ratio of 37.05, a PEG ratio of 1.97 and a beta of 0.98. The company has a debt-to-equity ratio of 2.51, a quick ratio of 2.83 and a current ratio of 4.27. Zoetis Inc has a 12 month low of $59.50 and a 12 month high of $89.25.
Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Wednesday, May 2nd. The company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.06. Zoetis had a net margin of 17.97% and a return on equity of 68.51%. The business had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.35 billion. During the same period in the prior year, the business posted $0.53 earnings per share. The company’s revenue was up 11.0% on a year-over-year basis. equities analysts forecast that Zoetis Inc will post 3.06 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 4th. Shareholders of record on Friday, July 20th will be given a dividend of $0.126 per share. The ex-dividend date is Thursday, July 19th. This represents a $0.50 annualized dividend and a yield of 0.57%. Zoetis’s payout ratio is 20.83%.
In other Zoetis news, insider Kristin C. Peck sold 4,877 shares of the company’s stock in a transaction dated Tuesday, May 1st. The shares were sold at an average price of $83.46, for a total transaction of $407,034.42. Following the completion of the sale, the insider now directly owns 42,652 shares in the company, valued at $3,559,735.92. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.35% of the company’s stock.
A number of analysts have recently weighed in on ZTS shares. Jefferies Financial Group set a $97.00 target price on shares of Zoetis and gave the stock a “buy” rating in a report on Monday, February 26th. Morgan Stanley downgraded shares of Zoetis from an “overweight” rating to an “equal weight” rating and set a $70.00 target price on the stock. in a report on Monday, March 19th. They noted that the move was a valuation call. ValuEngine upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Credit Suisse Group boosted their target price on shares of Zoetis from $83.00 to $89.00 and gave the stock an “outperform” rating in a report on Thursday, April 5th. Finally, Citigroup restated a “buy” rating and issued a $98.00 target price (up from $85.00) on shares of Zoetis in a report on Thursday, April 19th. One analyst has rated the stock with a sell rating, seven have given a hold rating and eleven have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $84.25.
Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.